Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab Open-Label Extension in SLE
NCT00660881Phase 2Completed
- Sponsor
- UCB
- Start
- May 2008
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of epratuzumab in systemic lupus erythematosus (SLE), sponsored by UCB. Primary endpoint: Adverse Events, Vital Signs, and Clinical Safety Laboratory Assessments. Started May 2008; status: completed.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00660881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00660881.